Model Informed Drug Development Archives | 第 10 页，共 44 页 | Certara

Blog

Be Honest, Be Reliable, Be Human: Insights from a Global Drug Development Expert

One of the most exciting things about working in the pharmaceutical industry is the ability…

Certara2020 年 12 月 16 日

Press Release

Certara Opens New China Office in Shanghai

Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D …

Certara2020 年 11 月 9 日

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

Certara2019 年 12 月 19 日

Poster

THE RELATIONSHIP BETWEEN mRNA AND ACTIVITY FOLLOWING INDUCTION OF CYP3A4 AND CYP2B6 ACROSS A RANGE OF PROTOTYPICAL INDUCERS

Certara2019 年 8 月 28 日

Poster

Prediction of Prothrombin Time after Oral Administration of S-Warfarin in Different CYP2C9 Phenotypes in Asian and Caucasian populations using the Simcyp Simulator

Certara2019 年 8 月 23 日

Poster

Prediction of Midazolam Concentration Profile in Obese Adolescent Population Using Physiologically Based Pharmacokinetic model

Certara2019 年 8 月 23 日

Poster

Prediction of Enfuvertide Concentration-Time Profile in a Paediatric Population after Parenteral Administration Using a Physiologically Based Pharmacokinetic Model

Certara2019 年 8 月 23 日

Poster

Simulating the effect of anti-diabetic drugs on ATP-sensitive potassium (KATP) channels inhibition in a human cardiac cell model (ORd)

Certara2019 年 8 月 23 日

海报

Application of a PBPK model for prediction of the DDI between Lorazepam and Probenecid.

Certara2019 年 8 月 22 日

Poster

What Sample Size to Use When Designing Paediatric Pharmacokinetic Studies? A Critical Analysis of “Precision Criteria”

Certara2019 年 8 月 22 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software